Osamah 1997.

Methods	no washout period required because no patient was receiving hypolipidaemic treatment 24‐week before and after trial
Participants	30 men 40‐70 years old 6 mmol/L < plasma TC < 8 mmol/L (232 mg/dL < plasmaTC < 309 mg/dL) plasma TG < 3 mmol/L (266 mg/dL) with no chronic or metabolic diseases, no acute coronary event Fluvastatin 40 mg/day baseline TC : 7.675 mmol/L (297 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 5.295 mmol/L (205 mg/dL) Fluvastatin 40 mg/day baseline triglycerides: 2.76 mmol/L (244 mg/dL)
Interventions	Fluvastatin 40 mg/day
Outcomes	per cent change from baseline at 4‐12 weeks of serum TC, LDL‐C, and triglycerides
Source of Funding	unknown
Notes	12‐24 week time period was not included in the efficacy analysis SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	High risk	16.7% participants were not included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported